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Abstract
The aim. Determine hemodynamic status and its impact on oxygen transport, frequency of adverse events and outcomes in 
patients with severe SARS-CoV-2 associated with acute respiratory distress syndrome (ARDS).
Materials and methods. A single-center prospective comparative study was conducted with 29 patients enrolled over the 
period of July-October 2020 who suffered a severe course of coronavirus disease and bilateral pneumonia associated with ARDS. 
Based on the estimated cardiac index (CI), patients were allocated to two groups: Group 1 included 14 patients with severe ARDS 
and CI 1.9 [1.5–2.5] L/min/m2, whereas Group 2 included 15 patients with CI 4.2 [3.2–8.1] L/min/m2 (p = 0.001). Patient’s intensive 
care was regulated by the relevant orders of the Ministry of Health of Ukraine. Statistical analysis of the results was carried out using 
Statistica 10 software. Statistical significance of parameters was assessed using the non-parametric Wilcoxon criterion. Results were 
considered significant at p values < 0.05. Data are presented as M [25–75]. Relative risk (RR) and odds ratio (OR) of adverse events 
were calculated.
Results. The severe course of coronavirus disease is associated with significant oxygen transport disorders that increase with 
hypovolemia. Despite the increase in oxygen delivery in the group with normal CI its high tissue extraction remained, which may be 
a sign of development mitochondrial distress.
Conclusions. Patients admitted to the ICU with severe COVID-19 may be in a state of hypovolemia and require individual 
assessment of hemodynamic status and the appointment of infusion therapy. Increased oxygen delivery in patients with normal car-
diac index was associated with decreased adverse events rate and statistically significant decrease of mortality rate.
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1. Introduction
The basis of critical care is this or that way related to control of oxygen transport and pre-
vention of its disorders or correction thereof. When oxygen transport is impaired due to heart 
failure or hypovolemia (for example due to bleeding), the causes of tissue hypoxia are clear and 
their correction is not challenging. Oxygen transport disorders are less clear in other severe condi-
tions such as ARDS, and sepsis [1, 2].
According to some study results, among patients admitted to hospital with COVID-19, 
33 % manifest with ARDS, 26 % require transfer to the intensive care unit (ICU), 16 % require me-
chanical ventilation (MV), and 16 % die [3, 4]. Among COVID-19 patients transferred to ICU 63 % 
require mechanical ventilation, and 75 % have ARDS [5]. A mortality rate of ICU patients with 
COVID-19 is 40 %, and 59 % of patients are on mechanical ventilation; a mortality rate related 
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to COVID-19-associated ARDS is 45 %, and ARDS rate among those who did not survive with 
COVID-19 is 90 % [6, 7].
The choice of infusion therapy strategy in patients with ARDS is still controversial. 
It should be noted that there are several causes of hemodynamic instability in patients with severe 
coronavirus disease. Firstly, hypovolemia due to fever and restrictive fluid therapy (that was used 
in early publications as the one preventing development of pulmonary edema). Secondly, the «cyto-
kine storm» may be associated with vasoplegic syndrome which may increase in patients receiving 
sedatives to synchronize patients with ventilators. The development of the cytokine storm and 
cytokine circulation in the bloodstream can also affect myocardial tissue and cause both systolic 
and diastolic dysfunction [8]. The use of positive end-expiratory pressure (PEEP) in patients on 
mechanical ventilation can affect the right ventricular (RV) relaxation and reduce the left ventricu-
lar (LV) systolic function through so-called interventricular interaction. In addition, patients with 
COVID-19 are prone to hypercoagulation disorders and development of thromboembolic complica-
tions which can be associated with critical changes in hemodynamic parameters [9].
Optimal administration of infusion solutions should ensure oxygen delivery avoiding hy-
pervolemia, pulmonary edema that impairs gas exchange. In studies published including patients 
with ARDS, the liberal type of infusion was associated with prolonged ventilation, stay in ICU, 
and increased mortality [10, 11]. With a restrictive type of infusion, investigators obtained better 
results in terms of oxygenation and shorter duration of mechanical ventilation, but no advantage 
in survival [12]. Therefore, nowadays, there is no single decision on the choice of infusion strategy 
for ARDS, with extremely limited data on COVID-19-related ARDS. ARDS is often known to 
be secondary to shock and may require more aggressive therapy. Bedside ultrasound examination 
allows to determine the hemodynamic status of the patient and provide targeted therapy, depending 
on the clinical case. 
The issue of oxygen transport in critical conditions became contentious once Shoemaker 
put forward the hypothesis of «supernormal» oxygen delivery. He defined this condition as car-
diac index (CI) > 4.5 L/min/m2, oxygen delivery (DO2) > 600 mL/min/m2, and oxygen consump-
tion (VO2) > 170 mL/min/m2 [13, 14]. In his study involving cardiac surgery patients, achieving 
«supernormal» DO2 values was associated with improved clinical outcomes. Repeated studies con-
firmed the hypothesis of a positive effect of increased oxygen delivery on preventing organ damage 
and improving the survival of these patients [14].
However, extrapolation of the hypothesis of «supernormal» oxygen delivery to other criti-
cally ill populations did not show any improvement in intensive care outcomes [14].
10 years later, Rivers used a similar method of early targeted therapy with maintenance 
of central venous saturation of at least 70 % and mean blood pressure (MBP) of at least 65 mm 
Hg, which caused repeated interest of intensive care physicians in the hemodynamic status of 
patients [14]. However, a number of subsequent studies failed to demonstrate the positive effect 
of early targeted therapy [15–17].
The conducted studies cause a series of discussions that are still ongoing [18–20]. In addi-
tion, the methods described above have not been studied before with involvement of patients with 
severe coronavirus disease complicated by ARDS.
Despite these facts, most of the literature data till nowadays are focused on the treatment 
of respiratory failure in patients with coronavirus disease, whereas no data are found in the pub-
lications of modern scientometric databases regarding hemodynamic effects and their impact on 
oxygen transport [21].
The aim: to determine the hemodynamic status and its impact on the oxygen transport, fre-
quency of adverse events and outcomes in patients with severe SARS-CoV-2 who develop ARDS.
2. Materials and methods
A single-center prospective comparative study was conducted with 29 patients enrolled over 
the period of July-October 2020 who suffered a severe course of coronavirus disease and bilateral 
pneumonia associated with ARDS. The study was conducted in the settings of Departments of 
Anesthesiology, Pediatric Anesthesiology and Intensive Care of Kharkiv Medical Academy 
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of Post-graduate Education, in the Intensive Care Unit of the Non-profit Municipal Enterprise of 
the Kharkiv Regional Council «Regional Clinical Infectious Disease Hospital».
Based on the cardiac index (CI), patients were allocated to two groups: with redu- 
ced CI (< 3 L/min/m2) and normal CI (> 3 L/min/m2). Group 1 included 14 patients with se-
vere ARDS and CI 1.9 [1.5–2.5] L/min/m2, whereas Group 2 included 15 patients with CI 
4.2 [3.2–8.1] L/min/m2 (p = 0.001).
Patients were thoroughly examined. The coronavirus disease was diagnosed using PCR 
with the isolation of SARS-nCoV RNA from the nasopharyngeal wash. Pneumonia was verified 
by chest CT scan or X-ray. ARDS was diagnosed according to the Berlin definition.
Body mass index (BMI) was calculated using the formula:
BMI = body weight/height2 (kg/m2)
Patients were examined in accordance with the accepted standards including the following 
tests: FBC, C-reactive protein, procalcitonin, lactate, D-dimer, and blood gas composition. FBC 
was performed using BC–2800 Mindray analyzer (China). C-reactive protein was evaluated by 
turbidimetric method (Biosystems kits, Spain). Biochemical tests were performed using Chemray 
120 Mindray biochemical analyzer (China). To monitor the haemostatic system condition, D-dimer 
was determined by the ELISA method (Vector-Best kits, Ukraine). 
Using Comen monitors (China), patients heart rate (HR) monitoring was performed using 
electrocardiography, mean blood pressure (MBP) using oscillometric method and pulse oxime-
try (SpO2), end-expiratory carbon dioxide measurement (etCO2 mm Hg).
The gas composition of arterial and central venous blood was evalueated using EDAN gas 
analyzer (China). 
Arterial oxygen concentration (CaO2) was determined using the calculation:
CaO2 (mL/100 ml) = ((1.34*Hb*SaO2)/1000)+(0.003*PaO2),
where Hb – hemoglobin, g/L; SaO2 – arterial blood saturation; PaO2 – partial pressure of arterial 
blood oxygen.
Central venous oxygen concentration (CvO2) was determined using the calculation:
CvO2 (mL/100 ml) = ((1.34*Hb*SvO2)/1000)+(0.003*PvO2),
where Hb – hemoglobin, g/L; SvO2 – central venous blood saturation; PvO2 – partial pressure of 
central venous blood oxygen.
Pulmonary capillaries oxygen concentration (CcO2) was calculated using the calculation:
CсO2 (mL/100 ml) = ((1.34*Hb*SaO2)/1000)+(0.003*PAO2),




Oxygen consumption (VO2) was determined using the calculation:
VO2 (mL/min/m2) = CI*(CaO2–CvO2).








All patients underwent daily bedside M-mode echocardioscopy using «Ultima PA» (Ukraine) 
ultrasound scanner. The left ventricular end-diastolic (EDD), end-systolic (ESD) dimensions 
and right ventricular EDD were measured. Based on the data obtained using Teichholz L. et al. 
formula (1976), left ventricular end-systolic (ESV) and end-diastolic (EDV) volumes, stroke 
volume (SV), and ejection fraction (EF) were calculated. 
The cardiac minute output (CMO) was calculated using the formula:
CMO = SV*HR.
The cardiac index (CI) was calculated using the formula:
CI = CMO/BSA,
where BSA is the body surface area calculated by the Mostller formula. 
Intensive care was provided to patients according to relevant orders of the Ministry of 
Health of Ukraine and included administration of anticoagulants, corticosteroids, infusion therapy, 
antibacterial agents on demand, remdesivir, use of sympathomimetics and sedatives on demand, 
treatment of concomitant diseases (coronary heart disease, hypertension, diabetes mellitus, etc.), 
symptomatic therapy [22–28]. 
All patients underwent mechanical ventilation using Hamilton C6, Newport E 360t, Monnal 75t, 
Graph Net and Extend XT machines with assessment of ventilation and pulmonary mechanics para-
meters: Vt (mL), MV (L/min), f (per min), Pin (cm H2O), Pmean (cm H2O), PEEP (cm H2O), FiO2 (%), 
Cst (mL/cm w.c.) using graphic monitors. The saturation index (OSI) was calculated using the formula:
OSI = (FiO2*Pmean*100)/SpO2,
where FiO2 is the oxygen fraction in the gas mixture, Pmean is the mean airway pressure.
Statistical analysis of the results was carried out using Statistica 10 software. The median, 
minimum and maximum values, and standard deviation were estimated. Statistical significance 
of parameters was assessed using the non-parametric Wilcoxon criterion. Results were considered 
significant at p values < 0.05. Data are presented as M [25–75]. Relative risk (RR) and odds ratio 
(OR) of adverse events were calculated.
3. Results 
The median age of patients in Group 1 was 68 [58.0–72.0] years, and in Group 2 – 
60.5 [45–73.5] years without significant differences between the groups (p > 0.05). The body mass 
index in Group 1 was 39.0 [32.0–46.0] kg/m2, and in Group 2 – 31.0 [28.0–36.0] kg/m2 (p > 0.05).
FBC in patients of the study groups showed moderate leukocytosis with a neutrophil shift 
with no significant differences between the groups (p > 0.05). C-reactive protein in the study groups 
was 10-fold higher than normal values and there were no significant differences revealed between 
the groups (p > 0.05). Procalcitonin was 0.2 [0.1–1.4] ng/mL in Group 1, and 0.6 [0.32–0.8] ng/mL 
in Group 2 (p > 0.05) (Table 1).
Table 1
Blood inflammatory response markers in patients of the study groups
Index, units Group 1 (n = 14) Group 2 (n = 15)
White blood cells, ×109/L 9.1 [7.9–13.4] 10.9 [10.8–16.1]]
Neutrophils, % 82.0 [79.0–84.0] 91.0 [87.0–94.0]
Lymphocytes, % 10.0 [9.0–16.0] 6.0 [5.0–8.0]
C-reactive protein, mg/L 58.0 [53.0–61.0] 59.3 [57.7–126.0]
Procalcitonin, ng/mL 0.2 [0.1–1.4] 0.6 [0.32–0.8]
Original Research Article:
full paper




To examine the hemostatic system condition D-dimer was determined and showed the level of 
2955.0 [354.0–4450.0] ng/mL in Group 1 and 246.0 [66.0–354.0] ng/mL in Group 2 that reflects the 
tendency towards hypercoagulation without significant differences between the groups (p > 0.05).
The saturation index (OSI) was 18.0 [12.0–24.0] in Group 1 and 12.0 [10.9–18.0] in Group 2 
and no significant differences between the groups were detected (p > 0.05). The obtained results 
indicate that patients in both groups have severe ARDS according to the Berlin definition (2012) 
that requires invasive respiratory support. Patients received pressure-controlled mechanical ven-
tilation in accordance with pulmonary protective principles. The average airway pressure was 
16.9 [16.0–21.8] cm H2O in Group 1, and 21.0 [14.0–21.8] cm H2O in Group 2 (p > 0.05). Static 
compliance did not significantly differ between the groups (p > 0.05) (Table 2).
Table 2
Pulmonary mechanics in patients of the study groups
Index, units Group 1 (n = 14) Group 2 (n = 15)
PEEP, cm H2O 14 [14–16] 14 [14–15]
P mean, cm H2O 16.9 [16.0–21.8] 21.0 [14.0–21.8]
Vt, mL 538.0 [410.0–642.0] 515.0 [440.0–565.5]
C stat, mL/cm w.c. 38.9 [34.8–55.8] 37.9 [32.6–43.9]
Thus, the patients included in the study had a severe course of coronavirus disease and did 
not differ significantly between the groups (p > 0.05). Therefore, it can be considered that the study 
groups of patients were comparable in severity of the condition.
The hemodynamic status in Group 2 patients showed a significant increase in EDV, ESV, 
SV and CMO. At the same time, what seems to be interesting is the maintenance of normal EF 
in both groups without significant differences (p > 0.05). That is, the decrease in Group 1 CI was 
associated with hypovolemia rather than primary heart weakness (Table 3).
Table 3
Central hemodynamic condition in patients of the study groups
Index, units Group 1 (n = 14) Group 2 (n = 15) p
MBP, mm Hg 101.3 [83.3–108.7] 100.3 [91.0–103.7] > 0.05
EDV, mL 78.1 [51.3–114.3] 144.5 [86.5–222.9] 0.001
ESV, mL 16.5 [11.3–38.6] 49.1 [24.3–150.1] 0.001
SV, mL 52.9 [40.0–71.1] 97.2 [62.2–150.1] 0.001
EF, % 65.2 [62.0–77.9] 67.4 [48.0–78.7] 0.51
CMO, L/min 3.7 [3.0–4.0] 9.1 [5.8–17.5] 0.01
CI, L/min/m2 1.9 [1.5–2.5] 4.2 [3.2–8.1] 0.001
Analysis of arterial blood gas composition was conducted in the study groups. The partial 
pressure of arterial blood oxygen was 81.0 [72.0–85.0] mm Hg in Group 1, and 103.0 [94.0–131.0] mm 
Hg in Group 2 with no significant differences between the groups (p > 0.05). However, the PaO2/FiO2 
ratio was significantly lower than normal and amounted to 81.5 [70.0–128.0] in Group 1 
and 107.0 [95.5–142.0] in Group 2 that corresponds to the severe course of ARDS in all pa-
tients (p > 0.05). Interestingly, PaO2 and SaO2 were higher in Group 2 than in Group 1. CO2 partial 
pressure did not significantly differ between the groups, but Group 1 showed a more pronounced 
tendency to hypocapnia. ∆CO2 (PaCO2 – etCO2) mm Hg can be explained by a significant ven-
tilation and perfusion impairment. Arterial blood lactate levels in both groups were higher than 
normal without significant differences between the groups (Table 4).
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Analysis of the central venous blood gas composition showed no significant differences 
between the groups (p > 0.05) (Table 5).
Table 4
Arterial blood gas analysis in the study groups
Index, units Group 1 (n = 14) Group 2 (n = 15)
pHa 7.44 [7.29–7.49] 7.39 [7.32–7.45]
PaО2, mm Hg 81.0 [72.0–85.0] 103 [94–131]
PaCO2, mm Hg 32.5 [28.3–40.1] 38.1 [34.3–46.7]
SaO2, % 95.0 [93.0–97.0] 98.0 [97.0–99.0]
etCO2 mm Hg 23.0 [17.0–28.0] 26.0 [22.0–30.0]
PaO2/FiO2 81.5 [70.0–128.0] 107.0 [95.5–142.0]
∆CO2 mm Hg 9.8 [7.8–12.1] 13.6 [10.2–20.9]
Lactate, mmol/L 3.4 [2.6–4.4] 5.3 [2.8–5.5]
Table 5
Central venous blood gas composition in patients of the study groups
Index Group 1 (n = 14) Group 2 (n = 15)
pH 7.40 [7.30–7.43] 7.38 [7.29–7.42]
PvO2 mm Hg 49.0 [42–50] 48.0 [43–55]
PvCO2 mm Hg 39.7 [36.8–50.7] 48.9 [37.2–56.3]
SvO2, % 82.0 [69.0–87.0] 82.0 [76.0–85.0]
etCO2, mm Hg 25.0 [17–31] 26.0 [23.0–29.0]
Arterial oxygen concentration was 15.7 [13.3–16.3] mL/100 mL in Group 1, and 
15.9 [13.3–17.9] mL/100 mL in Group 2 that corresponds to the lower limit of normal and has no sig-
nificant difference (p > 0.05). Central venous oxygen concentration was 11.9 [11.2–13.2] mL/100 mL 
in Group 1, and 13.0 [10.9–13.8] mL/100 mL in Group 2 and was lower than normal in both groups with-
out significant differences. Pulmonary capillaries oxygen concentration was normal in both groups – 
15.6 [13.3–16.2] mL/100 mL in Group 1 and 15.8 [13.2–17.8] mL/100 mL in Group 2, respectively.
Group 1 showed a significant reduction in oxygen consumption and delivery compared to 
Group 2 and normal values. In Group 1, these values corresponded to the lower limit of normal 
which is due to the severity of the patients’ conditions. Oxygen extraction (normal values 0.22–0.30) 
was 0.35 [0.26–0.51] in Group 1 and 0.38 [0.26–0.49] in Group 2 and had no significant differen-
ces, which is explained by a proportional reduction in oxygen delivery and consumption in Group 1 
patients (Table 6).
Table 6
Oxygen transport in patients of the study groups
Index, units Group 1 (n = 14) Group 2 (n = 15) p
CaO2, mL/100 mL 15.7 [13.3–16.3] 15.9 [13.3–17.9] > 0.05
CvO2, mL/100 mL 11.9 [11.2–13.2] 13.0 [10.9–13.8] > 0.05
CcO2, mL/100 mL 15.6 [13.3–16.2] 15.8 [13.2–17.8] > 0.05
VO2, mL/min/m2 103.0 [69.0–131.0] 268.0 [167.0–313.0] 0.008
DO2, mL/min/m2 264.0 [246.0–308.0] 652.0 [570.0–777.0] 0.008
O2ER 0.35 [0.26–0.51] 0.38 [0.26–0.49] > 0.05
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The average duration of ICU stay was 5 [4–7] days in Group 1 and 8 [5–14] days in Group 2, 
which indicates a longer life expectancy in Group 2 patients (p = 0.04). Frequency of adverse events 
was also analysed, among which acute kidney injury (AKI), pulmonary embolism (PE) and fatal 
outcomes can be noted. In Group 1, AKI was diagnosed in 8 patients (57.14 %), which is almost twice 
as much as in Group 2 – 4 (26.7 %). However, with calculation of RR 2.14 [0.83–5.56] (> 0.05) and 
OR 3.67 [0.78–17.4] ( > 0.05) this indicator showed no significant differences between the groups. 
PE was diagnosed in 5 patients (35.7 %) of Group 1 and 3 patients (20.0 %) of Group 2. With RR 
1.78 [0.52–6.12] (p > 0.05), OR 2.22 [0.42–11.82] ( > 0.05), there were no significant differences 
between the study groups.
The overall mortality was 86.2 %; however, 14 (100 %) patients died in Group 1 who had 
reduced CI, and 11 (73.3 %) patients died in Group 2 with normal CI. The relative risk of fatal out-
comes was calculated: in Group 2, a significantly lower RR = 1.36 [1.01–1.85] (p = 0.046) was de-
termined. Thus, maintaining an adequate cardiac index is one of the key therapeutic strategies that 
are beneficial for the outcomes in patients with respiratory failure caused by coronavirus disease.
4. Discussion
The coronavirus disease has rapidly spread around the world over the past year. Most pa-
tients have a mild to moderate course, but about 5 % develop complications and require treatment 
in intensive care units. ARDS is the most common cause for ICU hospitalization [5]. Therefore, key 
modern guidelines for the treatment of coronavirus disease focus on the treatment of respiratory 
failure using various methods of ventilatory support [18, 20].
Due to insufficient data obtained to determine the optimal management strategy for these 
patients, basic principles of the Berlin definition are used in the therapy of COVID-19-associated 
ARDS, namely pulmonary protective ventilation and restrictive infusion therapy [2].
Thus, insufficient attention is paid to the hemodynamic status of patients. This is an import-
ant option, as one of the main tasks of intensive care for respiratory failure is to maintain adequate 
oxygen delivery. A significant share depends on maintaining a normal volemic status.
Our study showed that a significant number of patients admitted to ICU were hypovolemic. 
Analysis of the blood gas composition in this group shows a significant reduction in oxygen deli-
very and consumption compared to Group 2. It consequently led to a higher incidence of complica-
tions (AKI, PE) and significant increase in mortality.
In Group 2 where normovolemia was maintained, we obtained better intensive care out-
comes expressed as a significant increase in life expectancy and decrease in mortality. 
However, it remains interesting that even with maintained adequate oxygen delivery in pa-
tients, there was a tendency to increased oxygen consumption, which is reflected in high O2ER 
values. This situation can be assumed to be associated with the development of a «cytokine storm» 
that pathogenetically resembles the course of septic shock. In this case, management of patients 
with a critical course of COVID-19 should be based on an individual assessment of the clinical 
condition and probably more aggressive infusion therapy [21]. 
Therefore, the obtained results suggest the appropriateness to conduct similar studies with 
a larger patient population. Patients with COVID-associated ARDS probably need extension of 
recommendations for management, including monitoring of hemodynamics and liberalization of 
the infusion regimen.
Study limitations. Restrictions due to the involvement of a small sample of patients.
Prospects for further research. Will further develop the study of hemodynamics and oxy-
gen transport in patients with severe COVID-19 with the development of severe ARDS in order to 
improve the results of intensive care.
5. Conclusions
1. The severe and critical course of COVID-19 with the development of ARDS is associated 
with significant impairments in oxygen transport and consumption aggravated by hypovolemia.
2. In patients with COVID-19 – related ARDS, hypovolemia is associated with a signi-
ficant reduction in oxygen delivery (DO2 Group1 264.0 [246.0–308.0] mL/min/m2, group 2 – 
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652.0 [570.0–777.0] mL/min/m2) and consumption (VO2 group 1 – 1103.0 [69.0–131.0] mL/min/m2, 
group 2 – 268.0 [167.0–313.0] mL/min/m2) compared to patients with normal CI (p = 0.008).
3. The difference between CO2 is explained by severe ventilation and perfusion impair-
ments in patients with COVID-19.
4. Despite the increased oxygen delivery in the group with a normal cardiac index, its tissue 
extraction remained high 0.38 [0.26–0.49], which might be a sign of the mitochondrial distress.
5. Increased oxygen delivery in patients with a normal cardiac index was associa-
ted with reduced frequency of adverse events and significant decrease in mortality RR = 
= 1.36 [1.01–1.85] (p = 0.046).
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